nach oben

Annals of Nuclear Medicine

Erschienen in:

01.02.2012 | Review article

PET scanning in plastic and reconstructive surgery

verfasst von: Liodaki Eirini, Liodakis Emmanouil, Papadopoulos Othonas, Machens Hans-Günther, Papadopulos A. Nikolaos

Erschienen in: Annals of Nuclear Medicine | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

In this report we highlight the use of PET scan in plastic and reconstructive surgery. PET scanning is a very important tool in plastic surgery oncology (melanoma, soft-tissue sarcomas and bone sarcomas, head and neck cancer, peripheral nerve sheath tumors of the extremities and breast cancer after breast esthetic surgery), as diagnosis, staging, treatment planning and follow-up of cancer patients is based on imaging. PET scanning seems also to be useful as a flap monitoring system as well as an infection’s imaging tool, for example in the management of diabetic foot ulcer. PET also contributes to the understanding of pathophysiology of keloids which remain a therapeutic challenge.

Saif MW, Tzannou I, Makrilia N, Syrigos K. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med. 83(2):53–65.

Bybel B, Brunken RC, Shah SN, Wu G, Turbiner E, Neumann DR. PET and PET/CT imaging: what clinicians need to know. Clevel Clin J Med. 2006;73(12):1075–87.CrossRef

Israel O, Keidar Z, Iosilevsky G, Bettman L, Sachs J, Frenkel A. The fusion of anatomic and physiologic imaging in the management of patients with cancer. Semin Nucl Med. 2001;31(3):191–205.PubMedCrossRef

Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med. 2003;44(5):717–24.PubMed

Dancey AL, Mahon BS, Rayatt SS. A review of diagnostic imaging in melanoma. J Plast Reconstr Aesthet Surg. 2008;61(11):1275–83.PubMedCrossRef

Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med. 2003;28(12):961–5.PubMedCrossRef

Prichard RS, Hill AD, Skehan SJ, O’Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg. 2002;89(4):389–96.PubMedCrossRef

Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ III, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-d-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104(3):570–9.PubMedCrossRef

Acland KM, Healy C, Calonje E, O’Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19(10):2674–8.PubMed

10.

Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol. 2003;29(8):662–4.PubMedCrossRef

11.

Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004;14(2):141–5.PubMedCrossRef

12.

Maubec E, Lumbroso J, Masson F, Suciu V, Kolb F, Mamelle G, et al. F-18 fluorodeoxy-d-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res. 2007;17(3):147–54.PubMedCrossRef

13.

Etchebehere EC, Romanato JS, Santos AO, Buzaid AC, Camargo EE. Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma. Nucl Med Commun. 2010;(11):925–30.

14.

Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89(5):1019–25.PubMedCrossRef

15.

Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M. Clinical presentation and imaging of bone and soft-tissue sarcomas. Clevel Clin J Med. 2010;77 Suppl 1:S2–S7.

16.

Lietman SA, Joyce MJ. Bone sarcomas: overview of management, with a focus on surgical treatment considerations. Clevel Clin J Med. 2010;77 Suppl 1:S8–S12.

17.

Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology. 2007;245(3):839–47.PubMedCrossRef

18.

Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med. 2003;28(10):815–20.PubMedCrossRef

19.

Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg. 2000;231(3):380–6.PubMedCrossRef

20.

Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44(8):1200–9.PubMed

21.

Bleeker-Rovers CP, de Kleijn EM, Corstens FH, van der Meer JW, Oyen WJ. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging. 2004;31(1):29–37.PubMedCrossRef

22.

Franzius C, Daldrup-Link HE, Wagner-Bohn A, Sciuk J, Heindel WL, Jurgens H, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol. 2002;13(1):157–60.PubMedCrossRef

23.

Daldrup-Link HE, Reinlander C, Link TM, Richter KJ, Konemann S, Rummeny EJ. Experimental studies of the value of SPIO for MRI of bone marrow before and after whole body irradiation. Rofo. 2001;173(6):547–53.PubMedCrossRef

24.

Hamada K, Tomita Y, Inoue A, Fujimoto T, Hashimoto N, Myoui A, et al. Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann Nucl Med. 2009;23(1):89–95.PubMedCrossRef

25.

Aoki J, Watanabe H, Shinozaki T, Takagishi K, Tokunaga M, Koyama Y, et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skelet Radiol. 2003;32(3):133–8.CrossRef

26.

Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med. 2008;22(7):603–9.PubMedCrossRef

27.

Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, Schwaiger M. Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol. 2009;2009:208725.PubMed

28.

Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Werning JW, Villaret DB. Definitive radiotherapy for squamous cell carcinoma of the base of tongue. Am J Clin Oncol. 2006;29(1):32–9.PubMedCrossRef

29.

Hustinx R, Lucignani G. PET/CT in head and neck cancer: an update. Eur J Nucl Med Mol Imaging. 2010;37(3):645–51.

30.

Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010;116(2):451–8.

31.

Kobe K, Chin T, Aoki R, Hyakusoku H. A false-positive fluorodeoxyglucose positron emission tomography (FDG-PET) imaging result for a patient after augmentation mammaplasty. Aesthet Plast Surg. 2009;33(4):611–5.CrossRef

32.

Deapen D, Hamilton A, Bernstein L, Brody GS. Breast cancer stage at diagnosis and survival among patients with prior breast implants. Plast Reconstr Surg. 2000;105(2):535–40.PubMedCrossRef

33.

Muzaffar AR, Rohrich RJ. The silicone gel-filled breast implant controversy: an update. Plast Reconstr Surg. 2002;109(2):742–7. (quiz 8).PubMedCrossRef

34.

Kang BJ, Kim SH, Choi JJ, Lee JH, Cha ES, Kim HS, et al. The clinical and imaging characteristics of breast cancers in patients with interstitial mammoplasty. Arch Gynecol Obstet. 2010;281(6):1029–35.

35.

Schrey AR, Aitasalo KM, Kinnunen IA, Laaksonen MS, Parkkola RK, Taittonen MT, et al. Functional evaluation of microvascular free flaps with positron emission tomography. J Plast Reconstr Aesthet Surg. 2006;59(2):158–65.PubMedCrossRef

36.

Schrey AR, Kinnunen IA, Grenman RA, Minn HR, Aitasalo KM. Monitoring microvascular free flaps with tissue oxygen measurement and PET. Eur Arch Otorhinolaryngol. 2008;265(Suppl 1):S105–13.PubMedCrossRef

37.

Oliver C, Muthukrishnan A, Mountz J, Deeb E, Johnson J, Deleyiannis F. Interpretability of PET/CT imaging in head and neck cancer patients following composite mandibular resection and osteocutaneous free flap reconstruction. Head Neck. 2008;30(2):187–93.PubMedCrossRef

38.

Schrey A, Niemi T, Kinnunen I, Minn H, Vahlberg T, Kalliokoski K, et al. The limitations of tissue-oxygen measurement and positron emission tomography as additional methods for postoperative breast reconstruction free-flap monitoring. J Plast Reconstr Aesthet Surg. 2010;63(2):314–21.PubMedCrossRef

39.

Luu Q, Farwell DG. Advances in free flap monitoring: have we gone too far? Curr Opin Otolaryngol Head Neck Surg. 2009;17(4):267–9.PubMedCrossRef

40.

Ozawa T, Okamura T, Harada T, Muraoka M, Ozawa N, Koyama K, et al. Accumulation of glucose in keloids with FDG-PET. Ann Nucl Med. 2006;20(1):41–4.PubMedCrossRef

41.

Zgonis T, Stapleton JJ, Rodriguez RH, Girard-Powell VA, Cromack DT. Plastic surgery reconstruction of the diabetic foot. AORN J. 2008;87(5):951–66. (quiz 67–70).PubMedCrossRef

42.

Nawaz A, Torigian DA, Siegelman ES, Basu S, Chryssikos T, Alavi A. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol. 2010;12(3):335–42.

43.

Keidar Z, Militianu D, Melamed E, Bar-Shalom R, Israel O. The diabetic foot: initial experience with 18F-FDG PET/CT. J Nucl Med. 2005;46(3):444–9.PubMed

44.

Schwegler B, Stumpe KD, Weishaupt D, Strobel K, Spinas GA, von Schulthess GK, et al. Unsuspected osteomyelitis is frequent in persistent diabetic foot ulcer and better diagnosed by MRI than by 18F-FDG PET or 99mTc-MOAB. J Intern Med. 2008;263(1):99–106.PubMed

45.

Crymes WB Jr, Demos H, Gordon L. Detection of musculoskeletal infection with 18F-FDG PET: review of the current literature. J Nucl Med Technol. 2004;32(1):12–5.PubMed

46.

Papadopulos NA, Schaff J, Biemer E. The use of free prelaminated and sensate osteofasciocutaneous fibular flap in phalloplasty. Injury. 2008;39(Suppl 3):S62–7.PubMedCrossRef

47.

Papadopulos NA, Schaff J, Biemer E. Long-term fate of the bony component in neophallus construction with free osteofasciocutaneous forearm or fibula flap in 18 female-to-male transsexuals. Plast Reconstr Surg. 2002;109(3):1025–30. (discussion 31–2).PubMedCrossRef

Titel: PET scanning in plastic and reconstructive surgery
verfasst von: Liodaki Eirini
Liodakis Emmanouil
Papadopoulos Othonas
Machens Hans-Günther
Papadopulos A. Nikolaos
Publikationsdatum: 01.02.2012
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 2/2012
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-011-0557-0

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Usefulness of breast-specific gamma imaging as an adjunct modality in breast cancer patients with dense breast: a comparative study with MRI

The agreement of left ventricular function parameters between 99mTc-tetrofosmin gated myocardial SPECT and gated myocardial MRI

Use of an oral effervescent agent in the evaluation of gastric 67Ga uptake

Effect of glycosylation on biodistribution of radiolabeled glucagon-like peptide 1

Erratum to: Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT

Correlated regions of cerebral blood flow with clinical parameters in Parkinson’s disease; comparison using ‘Anatomy’ and ‘Talairach Daemon’ software